Release Date: June 28, 2012
Source: Corporate News Center
With the continued global demand growth for high-quality peptide raw materials and lyophilized formulations, UTop Pharma announced in June 2012 that its new lyophilization production line had been successfully completed and officially put into operation.
The commissioning of this production line marks a 300% increase in annual lyophilization capacity and represents a significant leap for the company — from “production capability” to “large-scale industrial manufacturing.”
Over the past few years, UTop Pharma has successfully expanded its domestic and international markets with independently developed peptide synthesis and lyophilization technologies.
As the customer base grew rapidly and international orders surged, the existing production line faced capacity bottlenecks, making it increasingly difficult to ensure multi-batch, stable, and continuous supply.
After a comprehensive assessment of market demand and production utilization, the company launched the “Lyophilization Capacity Expansion Project” at the end of 2011.
The project aimed to achieve full upgrades in production efficiency, product consistency, and quality stability through equipment modernization and process re-engineering.
The new production line is equipped with state-of-the-art automated lyophilizers and an intelligent control system, featuring high-precision temperature regulation, automatic capping, vacuum monitoring, and real-time data recording capabilities.
Key technical highlights include:
Automated Control System: Enables intelligent monitoring of key parameters such as temperature, pressure, and time to ensure batch-to-batch consistency of lyophilization curves.
Process Analytical Technology (PAT): Real-time monitoring of sublimation progress and residual moisture, enhancing process control and product stability.
Energy Efficiency and Environmental Design: Incorporates refrigerant recycling and vacuum energy optimization systems, significantly reducing energy consumption and emissions.
All equipment fully complies with EU GMP and FDA 21 CFR Part 11 requirements, laying a solid quality foundation for further international market expansion.
The expansion also includes a 1,800-square-meter Class 100,000 clean production workshop, equipped with advanced air purification and temperature-humidity control systems to ensure cleanliness and safety throughout the entire manufacturing process.
The workshop layout follows a three-flow separation design — personnel, materials, and airflow — while all critical operation areas utilize sealed stainless-steel structures in full compliance with Good Manufacturing Practice (GMP) standards.
The quality control laboratory and central control room are digitally interconnected, forming a comprehensive traceability and data integration system.
The launch of the new lyophilization production line not only resolves current capacity constraints but also signifies UTop Pharma’s entry into a new era of large-scale, standardized, and globally integrated manufacturing.
This milestone enables the company to optimize its supply chain, shorten delivery cycles, and enhance responsiveness and service experience for international clients.
“We firmly uphold the principle that speed can be accelerated, but quality can never be compromised.
The new automated line allows us to serve global customers with higher efficiency and greater consistency.”
— Director of Production and Operations, UTop Pharma
At present, UTop Pharma has established long-term supply agreements with multiple partners across Europe, Southeast Asia, and the Middle East, ensuring stable production capacity to support future global expansion.
UTop Pharma will continue to focus on technological innovation and lean manufacturing as core drivers of growth.
The company is actively planning Phase II of the expansion project, which will further enhance product diversity and automation levels in lyophilized production.
Over the next three years, the company aims to increase total production capacity fivefold, covering a broader range of applications — including medical peptides, cosmetic active ingredients, and special nutrition materials.
In 2012, the successful commissioning of the new lyophilization production line marks another important milestone in UTop Pharma’s development journey.
This is not merely a capacity upgrade, but a vivid demonstration of the company’s manufacturing excellence and reliable global supply capabilities.
UTop Pharma firmly believes that only through continuous innovation and uncompromising quality can a brand win a broader and brighter future.
Issued by: Production and Operations Center
Editor: Corporate Branding Department
Date of Publication: June 28, 2012
